Literature DB >> 12547017

Selective retinoids and rexinoids in cancer therapy and chemoprevention.

F Christopher Zusi1, Matthew V Lorenzi, Valerie Vivat-Hannah.   

Abstract

Natural and synthetic retinoids are effective inhibitors of tumor cell growth in vitro and in vivo. However, the toxicity of natural derivatives of vitamin A limits their therapeutic use. Recently, synthetic compounds selective for the different retinoid receptor isotypes have been generated that circumvent pan-retinoid toxicity. The tumor-suppressive activity of selective retinoid and/or rexinoid ligands has been established preclinically, and emerging clinical trials are supportive of the chemotherapeutic and chemopreventive potential of these compounds in multiple oncology indications, with reduced toxicity. Moreover, the combination of retinoids and/or rexinoids with chemotherapeutic agents for the synergistic modulation of specific pathways could also be of benefit in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12547017     DOI: 10.1016/s1359-6446(02)02526-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  15 in total

1.  QM/MM refinement and analysis of protein bound retinoic acid.

Authors:  Xue Li; Zheng Fu; Kenneth M Merz
Journal:  J Comput Chem       Date:  2011-11-23       Impact factor: 3.376

2.  CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells.

Authors:  Yuan-Shan Fu; Qian Wang; Jing-Xin Ma; Xiang-Hong Yang; Mo-Li Wu; Kai-Li Zhang; Qing-You Kong; Xiao-Yan Chen; Yuan Sun; Nan-Nan Chen; Xiao-Hong Shu; Hong Li; Jia Liu
Journal:  Mol Oncol       Date:  2011-11-25       Impact factor: 6.603

3.  Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents.

Authors:  Lian Chen; Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Eun-Jung Park; Tamara P Kondratyuk; John M Pezzuto; Richard B van Breemen; Mark Cushman
Journal:  J Med Chem       Date:  2012-06-19       Impact factor: 7.446

4.  A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Authors:  Jill M Kolesar; Ryan Hoel; Marcia Pomplun; Tom Havighurst; Jeanne Stublaski; Barbara Wollmer; Helen Krontiras; Wayne Brouillette; Donald Muccio; Kyungmann Kim; Clinton J Grubbs; Howard E Bailey
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

5.  Pharmacological activity of retinoic acid receptor alpha-selective antagonists in vitro and in vivo.

Authors:  Sanny S W Chung; Rebecca A D Cuellar; Xiangyuan Wang; Peter R Reczek; Gunda I Georg; Debra J Wolgemuth
Journal:  ACS Med Chem Lett       Date:  2013-05-09       Impact factor: 4.345

6.  Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells.

Authors:  Qiuyan Chen; A Catharine Ross
Journal:  Exp Cell Res       Date:  2004-07-01       Impact factor: 3.905

7.  Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha.

Authors:  Giovanna Zappala; Cem Elbi; Joanna Edwards; Julie Gorenstein; Matthew M Rechler; Nisan Bhattacharyya
Journal:  Endocrinology       Date:  2007-12-27       Impact factor: 4.736

8.  Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.

Authors:  Martin Conda-Sheridan; Eun-Jung Park; Daniel E Beck; P V Narasimha Reddy; Trung X Nguyen; Bingjie Hu; Lian Chen; Jerry J White; Richard B van Breemen; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2013-03-08       Impact factor: 7.446

9.  Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.

Authors:  Hilal Kocdor; Mehmet Ali Kocdor; Tulay Canda; Duygu Gurel; Ruksan Cehreli; Osman Yilmaz; Mehmet Alakavuklar; Gul Guner
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

Review 10.  Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas.

Authors:  Marta Labeur; Marcelo Paez-Pereda; Eduardo Arzt; Günter K Stalla
Journal:  Rev Endocr Metab Disord       Date:  2008-07-07       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.